32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer: A randomized trial

Journal of Gastrointestinal Surgery

Volumn 12, Issue 4, 2008, Pages 682-688

  Rosemurgy, Alexander ^a   Luzardo, German ^a   Cooper, Jennifer ^a   Bowers, Carl ^a   Zervos, Emmanuel ^a   Bloomston, Mark ^a   Al Saadi, Sam ^a   Carroll, Robert ^a   Chheda, Hemant ^a   Carey, Larry ^a   Goldin, Steven ^a   Grundy, Shane ^a   Kudryk, Bruce ^a   Zwiebel, Bruce ^a   Black, Thomas ^a   Briggs, John ^a   Chervenick, Paul ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

32P; Pancreatic cancer; Trial

Indexed keywords

FLUOROURACIL; PHOSPHORUS;

ADENOCARCINOMA; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PHOSPHORUS RADIOISOTOPES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 40849105030     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-007-0430-6     Document Type: Article

References (21)

1. American Cancer Society. (2006). Last accessed October 17th 2006. How Many People Get Pancreatic Cancer? Available: http://www.cancer.org/docroot/CRI/ content/CRI_2_2_1X_How_many_people_get_pancreatic_cancer_34.asp?sitearea=
2. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK (eds). Last accessed October 17th 2006. SEER Cancer Statistics Review, 1975-2002, National Cancer Institute. Bethesda, MD. Available: http://seer.cancer.gov/csr/1975_2002/
3. Cleary SP, Gryfe R, Guindi M, Gremig P, Smith L, Mackenzie R, Strasberg S, Hanna S, Taylor B, Langer B, Gallinger S. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Amer Coll Surg 2004;198:722-731.
4. Kindler HL. Front-line therapy of advanced pancreatic cancer. Semin Oncol 2005;32(6 Suppl 9):S33-S36.
5. Ammori JB, Colletti LM, Zalupski MM, Eckhauser FE, Greenson JK, Dimick J, Lawrence TS, McGinn CJ. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 2003;7:766-772.
6. Freelove R, Walling AD. Pancreatic cancer: diagnosis and management. American Family Physician 2006;73:485-492.
7. Shipley WU, Nardi GL, Cohen AM, et al. Iodine-125 implant and external beam irradiation in patients with localized pancreas cancer. A comparative study to surgical resection. Cancer 1980;45:709-714.
8. Peretz T, Nori D, Hilaris BS, et al. Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation. Int J Radiat Oncol Biol Phys 1989;17:931-935.
9. Pfreunder L, Baier K, Schwab F, et al. 3d-Ct-planned interstitial HDR brachytherapy + percutaneous irradiation and chemotherapy in inoperable pancreatic carcinoma. Methods and clinical outcome. Strahlenther Onkol 1998;174:133-141.
10. Bargell BB. Radiation therapy with either gold grain implant or neuron beam for unresectable adenocarcinoma of the pancreas. In Cohn I, ed. Pancreatic Cancer New Directions in Therapeutic Management. New York: Masson Publishing, 1981, pp 55-62.
11. Westlin JE, Anderson-Forsman C, Garske U, et al. Objective responses after fractionated infusional brachytherapy of unresectable pancreatic adenocarcinomas. Cancer 1997;80(12 suppl):2743-2748.
12. Firusian N, Dempke W. An early phase II study of intratumoral P-32 chromic phosphate injection therapy for patients with refractory solid tumors and solitary metastases. Cancer 1999;85:980-987.
13. Order SE, Siegel JA, Principato R, et al. Selective tumor irradiation by infusional brachytherapy in nonresectable pancreatic cancer: a phase one study. Int J Rad Oncol 1996;36:117-125.
14. 32P. Ann Acad Med Singapore 1996;25:347-351.
15. Order SE, Siegel JA, Lustig RA, et al. Infusional brachytherapy in the treatment of non-resectable pancreatic cancer: a new radiation modality (preliminary report of a phase I study). Antib Immunoconjug, Radiopharm 1994;7:11-27.
16. Order SE, Siegel JA, Lustig RA, et al. A new method for delivering radioactive cytotoxic agents in solid cancers. Int J Radiat Oncol Biol Phys 1994;30:715-720.
17. Order SE, Lustic RA, Principato R, et al. Infusional brachytherapy: selective high dose radiation in solid cancers. Proc of Am Soc Clin Oncol 1995;14:482.
18. Niederhuber J. Surgical Interventions in Cancer. In Abeloff M ed. Clinical Oncology. 3rd ed. Orlando, Florida: Churchill Livingstone, 2004, pp 587.
19. Capital Technology Information Services Inc for NCI. (2002). Last accessed October 17th 2006. NCI Common Toxicity Criteria. Available: http://www.accessdata.fda.gov/scripts/cder/onctools/toxicity.cfm
20. Lilly Oncology. (2005). Last accessed October 17th 2006. GEMZAR® (GEMCITABINE HCl) FOR INJECTION. Available: http://pi.lilly.com/us/gemzar.pdf
21. Zubilliaga MB, Boccio JR, Nicolinni JO, et al. Use of colloids of chromic [32P] phosphate in treatment of solid tumors. Nucl Med Biol 1996;23:907-910.